Texas Biotech: Resilient Amid Challenges

Texas biotech companies, like the broader industry, are navigating global headwinds including tighter access to capital, shifting regulatory policies, and uncertainty around tariffs and federal funding. Business leaders are adapting strategies to remain agile in this evolving environment.

Despite these challenges, Texas biotechs continue to shine. Over the past 18 months, they’ve made a notable impact on the IPO market, while venture capital investment has grown year over year, signaling investor confidence in promising science. Public biotech revenue in Texas rose 27% in 2024 compared to 2023, with similar growth expected in 2025.

Though funding and execution hurdles remain, Texas’ biotech sector is proving resilient, innovative, and well-positioned for continued success.

Learn more